Premium
Treatment of Pediatric Malignant Tumors with VP‐16
Author(s) -
Ito Masahiro,
Kamiya Hitoshi,
Sakurai Minoru,
Akiyama Yuichi,
Mikawa Haruki,
Kawa Keisei,
Tujino Giichi,
Ueda Kazuhiro,
Miyazaki Sumio
Publication year - 1990
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/j.1442-200x.1990.tb00828.x
Subject(s) - medicine , leukopenia , mucositis , complete remission , malignant histiocytosis , chemotherapy , leukemia , gastroenterology , surgery , pathology , histiocyte
The West Japan Pediatric Oncology Group studied the treatment of pediatric malignant tumors with VP‐16 from December 1984 to March 1988. Study subjects were divided into two groups. One group received only VP‐16, while the other received VP‐16 combined with other anti‐tumor agents. VP‐16 evaluation was possible in a total of 116 cases. The efficacy rate was calculated by considering both complete and partial remission as effective. The efficacy rate for VP‐16 alone was 87.5% for primary cases of ANLL and 100% for primary cases of histiocytosis. The efficacy rates for combination therapy were as follows: 92.6% for primary cases of ANLL, 66.7% for primary cases of histiocytosis, 45.5% for relapsed cases of ANLL and 66.7% for relapsed cases of ALL. Bone marrow suppression was seen in the form of leukopenia and thrombocytopenia for 2 to 3 weeks after VP‐16 administration. Alopecia, mucositis and gastrointestinal symptoms were also observed, but they presented no significant problem. From our results, we believe that chemotherapy including VP‐16 is effective for remission induction therapy in primary cases of ANLL and for salvage therapy in relapsed leukemia. Additionally, VP‐16 is considered to be effective for the treatment of histiocytosis.